SurModics (SRDX) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. MRVL
2. USO
3. SPY
4. BBIO
5. NVDA
6. OPCH
7. GOOGL
8. AMD
9. CHRW
10. NEOG

Go back to SurModics (SRDX) Reports In-Line Q3 EPS

Surmodics Reports Third Quarter Fiscal 2021 Results and Updates Fiscal 2021 Revenue and EPS Guidance

August 4, 2021 7:30 AM EDT

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 third quarter ended June 30, 2021 and updated its financial outlook for its fiscal 2021.

Summary of Third Quarter and Recent Highlights

Revenue of $23.9 million, a decrease of 11% year-over-year GAAP EPS of $(0.24), non-GAAP EPS of $(0.17) PMA submission completed for SurVeil drug-coated balloon FDA 510(k) clearance received for Sublime .018 RX PTA Dilatation Catheter Successful first patient... More